Livzon Pharmaceutical repurchases A shares, signals ongoing capital management

Livzon Pharmaceutical Group announced the repurchase of 127,200 A shares on September 19, 2025, through the Shenzhen Stock Exchange. The repurchases were executed at prices ranging from RMB 39.08 to RMB 39.63 per share, totaling RMB 4,998,667. Following this transaction, the company's total issued A shares remained at 604,293,313.

The company's A-share repurchase program has been ongoing, with multiple transactions documented throughout late 2024 and 2025. These repurchases indicate a proactive approach to managing its share capital and potentially enhancing shareholder value.

The next day disclosure return, filed on September 19, 2025, confirms that all transactions comply with relevant listing rules and legal requirements, and no changes were made to the company's H share capital.